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Abstract
Necrotizing scleritis is the most severe and destructive form of scleritis with vision-threatening sequelae. It is divided
into with inflammation and without inflammation (scleromalacia perforans). Adalimumab is a tumour necrosis factor
(TNF)-inhibiting anti-inflammatory medication licensed for the treatment of rheumatoid and psoriatic arthritis,
ankylosing spondylitis and inflammatory bowel disease (in the USA). We report two cases of necrotizing scleritis
successfully treated with adalimumab.
Keywords: Necrotizing scleritis, TNF inhibitors, Adalimumab
Case report
Case 1
A 40-year-old lady presented with a history of scleritis
for which she was on oral prednisolone for over 1 year
with doses ranging from 10 to 80 mg per day. She had
pain and discomfort. Her visual acuity was 6/6 and poster-
ior segment was normal. Examination revealed an area of
scleral necrosis.
As her scleritis was active, she was commenced on
prednisolone 80 mg and mycophenolate mofetil (MMF)
(Cellcept) 500 mg BD, increasing to 750 mg BD. However,
she had severe gastric discomfort and nausea and was un-
able to continue with MMF. She was subsequently put on
tacrolimus (Prograf) 7.5 mg but developed nausea and
lethargy on this. She was unable to reduce oral steroids
whilst oral immunosuppression was tried. She was then
started on adalimumab (Humira) subcutaneous 40 mg
fortnightly and methotrexate 12.5 mg OD and achieved
resolution and control of scleral necrosis after 4 weeks.
During the course of treatment, she developed one
episode of gastroenteritis during which she missed her
Humira. At 9-month follow-up, the disease has
remained quiet on two weekly subcutaneous adalimu-
mab treatments.
Case 2
A 52-year-old lady with known rheumatoid arthritis and
refractory necrotizing scleritis poorly controlled with
oral prednisolone 10–80 mg and oral methotrexate
15 mg once a week was referred for treatment. Her visual
acuity was 6/9 in both eyes. Slit lamp examination re-
vealed acute scleral necrosis and impending perforation
as shown in Figs. 1 and 2.
Her past medical history included one episode of scleral
perforation to the left eye treated with amniotic patch
graft. The patient was started on two weekly subcutaneous
adalimumab 40 mg and achieved resolution and control of
scleral necrosis after 8 weeks. At 6-month follow-up, the
disease has remained quiet on two weekly subcutaneous
adalimumab treatments (Fig. 3).
Side effects during treatment included one episode of
shingles.
Discussion
Necrotizing scleritis represents 10–15 % of cases of an-
terior scleritis and is the most severe [1]. Left untreated,
necrotizing scleritis has a rapid and destructive course
that can be sight threatening.
Conventional treatment for recurrent or severe cases
of necrotizing scleritis involves immunosuppression
therapy and high-dose oral steroids [2]. Side effects asso-
ciated with these treatments and a poor response may
require patients to terminate treatment (as did our two
patients), making this condition very difficult to manage.
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Fig. 1 Scleral necrosis RE
Fig. 2 Scleral necrosis LE
Fig. 3 Resolution/control on adalimumab at 6-month follow-up
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The predominant cytokine TNF-alpha induces the matrix
metalloproteinases (MMPs) enzymes, MMP-3 and MMP-9
[3]. These are predominantly responsible for the de-
struction of the scleral wall and adjacent cornea in severe
scleritis, particularly associated with necrosis [4].
Infliximab (Remicade Centocor, Johnson & Johnson,
USA) and adalimumab (Humira, Abbott Laboratories,
Chicago, IL) are monoclonal antibodies that recognise,
bind to and inhibit TNF, thereby decreasing inflammation.
Infliximab has shown long-term efficacy in the treatment
of refractory posterior uveitis [5]. Published literature has
reported improvement in patients with either idiopathic
scleritis or scleritis associated with systemic disease treated
with infliximab [6].
Ragam et al. evaluated the use of TNF inhibitors inflix-
imab and adalimumab in 17 patients with non-infectious
and non-necrotizing scleritis and achieved control of ac-
tive inflammation for at least 2 months in 15 (88 %) of
17 patients [7].
Adalimumab has been reported as successful in the
treatment of bilateral idiopathic nodular scleritis (with
no side effects reported) [8] and nodular scleritis associ-
ated with RA [9].
Morarji et al. reported the successful treatment of
necrotizing scleritis (secondary to granulomatosis with
polyangiitis) with infliximab whilst waiting for rituximab
to induce disease remission [10]. Two intravenous 1-g
doses of rituximab (MabThera, Hoffmann-La Roche, Ltd.)
(a chimeric murine and human monoclonal antibody di-
rected against the CD20 antigen [11]) were used, given
2 weeks apart. However after 3 weeks, the necrotizing
scleritis was still active. Therefore, infusions of infliximab
(Remicade, Merck & Co.) 5 mg/kg doses at baseline, 2, 6
and 12 weeks were given, controlling the necrotizing scler-
itis by week 6. This enabled cyclophosphamide to be
avoided in the acute phase (as rituximab can take up to
6 months to work).
In this case series, we report two cases of refractory
necrotizing scleritis that were successfully treated with
adalimumab. During treatment, one patient developed
gastroenteritis and the other developed shingles.
Known potential side effects have been documented in
clinical trials and postmarket surveillance with TNF in-
hibitor use. The development of injection site reactions
[12], infusion reactions [12], and the reactivation of la-
tent tuberculosis [13] is increased with TNF inhibitor
use. Therefore, proper screening of patients with the
tuberculin skin test and chest x-ray and/or interferon
gamma assay should be performed prior to initiating
these therapies. Other side effects include the develop-
ment of demyelinating disease [14] and heart failure [15].
In conclusion, despite the risks involved with TNF inhibi-
tor use, with adequate screening of patients, the present case
series highlights that adalimumab offers a new tool for the
treatment of refractory necrotizing scleritis when conven-
tional treatments are contraindicated or have failed.
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